Effects of 0.005% latanoprost solution on intraocular pressure in healthy dogs and cats

American Journal of Veterinary Research

Volumn 61, Issue 10, 2000, Pages 1220-1224

  Studer, Michele E ^a   Martin, Charles L ^a   Stiles, Jean ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST;

ANIMAL EXPERIMENT; ARTICLE; BLEPHAROSPASM; CAT; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG FORMULATION; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PUPIL;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 0033819435     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.1220     Document Type: Article

References (45)

1. Fristrom B. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. Acta Ophthalmol Scand 1996;74:140-144.
2. Aim A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997;41(suppl):105-110.
3. Diestelhorst M, Roters S, Krieglstein GK. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour prolein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. Graefes Arch Clin Exp Ophthalmol 1997;235:20-26.
4. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-1752.
5. 2α analogue. Surv Ophthalmol 1997;41(suppl):77-81.
6. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost study group. Ophthalmology 1998;105:82-87.
7. Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996;9:363-378.
8. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multi-center trial in the United States. The United Slates latanoprost study group. Ophthalmology 1996;103:138-147.
9. Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost study group. Ophthalmology 1996;103:1916-1924.
10. 2α on cat and rhesus monkey eyes. Invest Ophthalmol Vis Sci 1982;22:588-598.
11. 2α isopropyl ester on intraocular pressure in normotensive and glaucomatous canine eyes. J Ocul Pharmacol 1991;7:107-116.
12. Bito LZ, Draga A, Blanco J, et al. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci 1983;24:312-319.
13. 2α analogue. In: Samuelsson B, ed. Advances in prostaglandin, thromboxane, and leukotriene research. New York: Raven Press Ltd, 1995;23:513-518.
14. 2α and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res 1996;63:305-310.
15. Zhan G, Miranda OC, Bito LZ. Steroid glaucoma: corticosteroid-induced ocular hypertension in cats. Exp Eye Res 1992;54: 211-218.
16. 2α-isopropylester eye drops: effects in normal human eyes. Br J Ophthalmol 1989; 73:419-426.
17. 2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 1989;96:1329-1337.
18. Mishima HK, Kiuchi Y, Takamatsu M, et al. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 1997;41(suppl):139-144.
19. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351-1358.
20. Bill A, Hellsing K. Production and drainage of aqueous humor in the cynomolgus monkey (Macaco irus). Invest Ophthalmol Vis Sci 1965;4:920-926.
21. Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. In: Samuelsson B, ed. Advances in prostaglandin, thromboxane, and leukotriene research. New York: Raven Press Ltd, 1995;23:519-525.
22. 2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res 1995;61:649-657.
23. 2α effects on intraocular pressure negatively correlate with FP-receptor stimulation. Invest Ophthalmol Vis Sci 1989;30:1838-1842.
24. Woodward DF, Lawrence RA, Fairbairn CE, et al. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies. J Lipid Mediat 1993;6:543-553.
25. Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol 1997; 41(suppl):61-68.
26. 2-induced ocular hyperemia. Exp Eye Res 1994;59:401-407.
27. Rulo AH, Greve EL, Geijssen HC, et al. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103: 1276-1282.
28. Pappas RM, Pusin S, Higginbotham EJ. Evidence of early change in iris color with latanoprost use. Arch Ophthalmol 1998;116: 1115-1116.
29. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-547.
30. Zhan GL, Toris CB, Camras CB, et al. Prostaglandin-induced iris color darkening. An experimental model. Arch Ophthalmol 1998;116:1065-1068.
31. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998;126:134-135.
32. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126: 37-41.
33. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol 1998;116:679-680.
34. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105:263-268.
35. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997;124: 683-685.
36. Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol 1998;116: 680-682.
37. Alm A Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res 1998;17:291-312.
38. Hollingsworth SR, Canton DD, Buyukmihci NC, et al. Effect of topically administered atropine on tear production in dogs. J Am Vet Med Assoc 1992;200:1481-1484.
39. Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure and pupil size in cats. Am J Vet Res 1991;52:436-440.
40. Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure and pupil size in dogs. Am J Vet Res 1991;52:432-435.
41. 3H-labeled dextran. Am J Vet Res 1985;46:84-88.
42. Woodward DF, Regan JW, Lake S, et al. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol 1997;41(suppl):15-21.
43. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 1997;38:2214-2223.
44. Bito LZ, Camras CB, Gum GG, et al. The ocular hypotensive effects and side effects of prostaglandins on the eyes of experi-mental animals. In: Bito LZ, Stjernschantz J, eds. The ocular effects of prostaglandins and other eicosanoids. New York: Alan R Liss Inc, 1989;349-368.
45. 2 and DP receptors. Invest Ophthalmol Vis Sci 1992;33:3195-3201.